Incidence of acute kidney injury among pediatric hematology/oncology patients receiving vancomycin in combination with piperacillin/tazobactam or cefepime | Zendy

Quach Henry T. | Zendy; Esbenshade Adam J. | Zendy; Zhao Zhiguo | Zendy; Banerjee Ritu | Zendy

Premium

Incidence of acute kidney injury among pediatric hematology/oncology patients receiving vancomycin in combination with piperacillin/tazobactam or cefepime

Author(s) -

Quach Henry T.,

Esbenshade Adam J.,

Zhao Zhiguo,

Banerjee Ritu

Publication year - 2019

Publication title -

pediatric blood and cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.116

H-Index - 105

eISSN - 1545-5017

pISSN - 1545-5009

DOI - 10.1002/pbc.27750

Subject(s) - cefepime , medicine , piperacillin/tazobactam , vancomycin , piperacillin , tazobactam , acute kidney injury , incidence (geometry) , antibiotics , staphylococcus aureus , microbiology and biotechnology , genetics , physics , optics , antibiotic resistance , imipenem , bacteria , pseudomonas aeruginosa , biology

There is mounting evidence that combination of antibiotic therapy with vancomycin and piperacillin/tazobactam (pip/tazo) is associated with acute kidney injury (AKI). To determine whether vancomycin plus pip/tazo is associated with higher rates of AKI compared to vancomycin plus cefepime among pediatric hematology/oncology (heme/onc) patients, we examined 121 heme/onc patients receiving at least two consecutive days of therapy with vancomycin and either pip/tazo or cefepime. Rate of AKI was higher in the pip/tazo than the cefepime group (4/27 [14.8%] vs 2/94 [2.1%], P = 0.022).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research